An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).Mariam Jamal‐Hanjani, Martin Förster, Kim Orchard et al.|Journal of Clinical Oncology|2021Cited by 5
Abstract 875: Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL productsEleni Kotsiou, Katy Newton, Tie Zheng Hou et al.|Cancer Research|2020Cited by 3
Abstract CT054: The development of a personalized autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical useHenrieta Fraser, Edward Samuel, Rebecca Pike et al.|Cancer Research|2020Cited by 0